News

Aldevron to provide new GMP Cas9 nuclease through agreement with Integrated DNA Technologies

Dec 12, 2017

SKOKIE, Ill. and SAN DIEGO (December 12, 2017) – Aldevron and Integrated DNA Technologies (IDT), Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFi™ Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.

“IDT continues to be an innovator for the biotechnology industry. We are excited to expand our partnership,” said Michael Chambers, Aldevron CEO. “This license will accelerate gene editing programs and help bring transformative treatments to patients. Aldevron’s 20 years of experience manufacturing biological material will allow us to provide our clients with SpyFi Cas9 Nuclease for use in research studies, clinical trials, and commercial applications.”

Mark Behlke, M.D., Ph.D., Chief Scientific Officer at IDT, added, “A significant amount of development effort went into making a S. pyogenes HiFi Cas9 mutant that worked in ribonucleoprotein formats, compatible with use in ex-vivo clinical protocols. We are excited to expand our collaboration with Aldevron to make available a full GMP version of this novel protein and to better serve the biomedical community, in addition to our traditional research markets.”

An advisory panel at the National Institutes of Health recently approved the first clinical trial using CRISPR-Cas9, which is planned to start by the end of the year. The project uses gene editing to augment cancer therapy by modifying a patient’s T cells. The technique has the potential to become a significant treatment in a wide variety of diseases.

Aldevron will have research grade SpyFi Cas9 nuclease available for shipment in December 2017. The company anticipates clinical grade SpyFi Cas9 Nuclease to be available in Q4 2018.

About IDT

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for many forms of cancer and most inherited and infectious diseases. Serving over 100,000 life sciences researchers and producing over 65,000 nucleic acids daily, IDT is widely recognized as the industry leader in custom nucleic acid manufacture. IDT has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Leuven, Belgium; and Singapore.

About Aldevron

Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from research grade to clinical trials to commercial applications. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source™ quality system. Company headquarters are in Fargo, N.D., with additional facilities in Madison, Wisc., and Freiburg, Germany.

Contact
Gwen Rosenberg
Vice President, Global Corporate Communications
Email: grosenberg@idtdna.com

IDT on Twitter

Follow us on twitter @idtdna for real-time updates and insights.

MEDIA INFORMATION

Learn about IDT's role in the fight against COVID-19

Media and PR

For media inquiries please contact IDT Public Relations, idtpr@idtdna.com